Fundraising Fox
Stuarttherapeutics
12 employees on LinkedIn · 1 known investors
Find your way into Stuarttherapeutics
Sign up to find every way you can get introduced to Stuarttherapeutics
- Your email: who you already know at Stuarttherapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Stuarttherapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Stuart Therapeutics is a clinical-stage pharmaceutical company developing synthetic collagen mimetic peptides (its PolyCol platform) designed to bind and repair damaged helical collagen in the extracellular matrix. Its therapies target chronic eye diseases including dry eye disease, glaucoma, and inherited retinal disorders such as retinitis pigmentosa and age-related macular degeneration.
Founders & leadership
Investors · 1
Frequently asked questions
- What does Stuarttherapeutics do?
- Stuart Therapeutics is a clinical-stage pharmaceutical company developing synthetic collagen mimetic peptides (its PolyCol platform) designed to bind and repair damaged helical collagen in the extracellular matrix. Its therapies target chronic eye diseases including dry eye disease, glaucoma, and inherited retinal disorders such as retinitis pigmentosa and age-related macular degeneration.
- Who founded Stuarttherapeutics?
- Stuarttherapeutics was founded by Robert O. Baratta.
- Who are Stuarttherapeutics's investors?
- Stuarttherapeutics's investors include BioBrit.